A Phase II Trial Of STI571 For The Treatment Of Platinum And Taxane Refractory Stage III And IV Epithelial Ovarian Cancer And Primary Peritoneal Cancer
Latest Information Update: 21 Apr 2023
Price :
$35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2005 New trial record.